The addition of intrathecal liposomal cytarabine to systemic treatment improves LM-related PFS. Confirmatory trials with optimized patient selection criteria and more active drugs may be required to demonstrate a survival benefit from intrathecal pharmacotherapy.
No takes yet. Share an insight, caveat, or question.
Rhun et al. (2019) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: